Allergan profit falls as Botox sales slump

By Staff Writers
Thursday, 28 April, 2005

Drugmaker Allergan said quarterly net earnings fell slightly, and sales of Botox missed analyst forecasts, sending shares down 2 per cent.

First-quarter profit was US$79.9 million, or 60 cents per share, compared with $80.8 million or 60 cents per share a year earlier.

Net sales rose to $527 million, from $472 million in the year earlier period.

Botox sales were $176 million, about $10 million short of analyst views.

Related News

Diabetes changes the structure of our hearts, study finds

Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...

Beta blockers could halt triple negative breast cancer

Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...

Common arthritis drug also lowers blood pressure

Scientists have known for a while that methotrexate helps with inflammation, but it may also help...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd